Passage Bio Inc. (PASG): Price and Financial Metrics


Passage Bio Inc. (PASG): $1.46

0.03 (+2.10%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PASG to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PASG Stock Price Chart Interactive Chart >

Price chart for PASG

PASG Price/Volume Stats

Current price $1.46 52-week high $5.33
Prev. close $1.43 52-week low $1.04
Day low $1.43 Volume 39,633
Day high $1.50 Avg. volume 159,610
50-day MA $1.38 Dividend yield N/A
200-day MA $1.77 Market Cap 79.65M

Passage Bio Inc. (PASG) Company Bio


Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.


PASG Latest News Stream


Event/Time News Detail
Loading, please wait...

PASG Latest Social Stream


Loading social stream, please wait...

View Full PASG Social Stream

Latest PASG News From Around the Web

Below are the latest news stories about PASSAGE BIO INC that investors may wish to consider to help them evaluate PASG as an investment opportunity.

Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted an inducement award to a new employee. Passage Bio granted options to purchase 7600 shares of common stock to this employee as material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price

Yahoo | January 20, 2023

After losing 67% in the past year, Passage Bio, Inc. (NASDAQ:PASG) institutional owners must be relieved by the recent gain

To get a sense of who is truly in control of Passage Bio, Inc. ( NASDAQ:PASG ), it is important to understand the...

Yahoo | January 7, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday!

William White on InvestorPlace | December 15, 2022

Passage Bio Stock Jumps After Gene Therapy Study In Lysosomal Storage Disorder

Passage Bio Inc (NASDAQ: PASG) announced new interim safety, biomarker, and clinical development results from cohorts 1-3 in the Imagine-1 Phase 1/2 study of AAVhu68 gene therapy PBGM01 for GM1 Gangliosidosis (GM1). GM1 is a rare, fatal lysosomal storage disease in which mutations in the GLB1 gene result in the deficient activity of the enzyme beta-galactosidase (β-Gal), an enzyme that helps break down fats and sugars. PBGM01 administration resulted in dose-dependent increases in CSF β-Gal activ

Yahoo | December 14, 2022

Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study

Interim safety data up to 20 months showed the low and high dose of PBGM01 were well tolerated and had a favorable safety profileIntra-cisterna magna administration of PBGM01 resulted in dose-dependent increases in CSF β-Gal activity and decreases in CSF GM1 gangliosidesPBGM01 administration resulted in a meaningful improvement across developmental areas in a subset of patients, as assessed by investigators and caretakersCompleted dosing of all patients in dose-ascending portion of study; initia

Yahoo | December 14, 2022

Read More 'PASG' Stories Here

PASG Price Returns

1-mo 5.80%
3-mo 16.80%
6-mo -31.46%
1-year -70.97%
3-year N/A
5-year N/A
YTD 5.80%
2022 -78.27%
2021 -75.17%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6502 seconds.